by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
by Annie De Groot | Sep 21, 2020 | Events, Webinars
Thank you for your continued interest in the status of our EpiVax’s EPV-CoV-19 Vaccine Program. This event has passed! But do not fear, there is a recording of the session available for access. Kindly fill out the information form linked below and an email...
by Adam | Apr 7, 2020 | News
PROVIDENCE, RI, April 7, 2020 /PRNewswire/ — EpiVax, Inc., is using advanced computational tools to accelerate a COVID-19 vaccine candidate (EPV-CoV19) for healthcare workers (HCW) into clinical trials in 6 months. Today, EpiVax announces its partnership with...
